A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...

No one disputes the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis—not even the cost watchdogs at the Institute for Clinical and Economic Review (ICER). But ...

Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

The results represent a "historic" moment in cystic fibrosis care. Vertex has announced successful results from two Phase III studies of Trikafta (elexacaftor ...

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...

Courtney Boccio wasn’t sure what to expect when she started a clinical trial for a new drug aimed at helping people with cystic fibrosis in the spring of 2018. The 25-year-old Huntington woman was ...

Yesterday, the FDA approved the use of Trikafta, a triple combination therapy, for treatment of the most common cystic fibrosis (CF) mutation. This is the first medication to be approved for use among ...